Inhaled nitric oxide in the premature infant: animal models and clinical experience

Inhaled nitric oxide (iNO) is an effective adjuvant therapy for term newborns with persistent pulmonary hypertension. However, its role in treating hypoxemic respiratory failure in premature newborns has not been established. Laboratory experiments have shown the importance of endogenously produced NO in fetal and neonatal pulmonary vasoregulation in the premature lamb. Moreover, low-dose iNO improves oxygenation and reduces pulmonary vascular resistance in the premature lamb with hyaline membrane disease. Preliminary studies have suggested the potential role of low-dose iNO in premature newborns with hyaline membrane disease, sepsis, and pulmonary hypoplasia. However, prematurity poses unique risks that must be carefully addressed with clinical trials designed to measure both safety and efficacy of this promising new therapy.